Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients
Conditions: Carcinoma, Basal Cell; Carcinoma, Cutaneous Squamous Cell Intervention: Drug: L19IL2 +L19TNF Sponsor: Philogen S.p.A. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Melanoma | Nonmelanoma Skin Cancer | Research | Skin | Skin Cancer